TuesdayDec 19, 2023 9:00 am

Oncologist Explores Whether Including Fiber in Diets Boosts Immunotherapy Outcomes

We all know that a diet  high in fiber is good for us, with studies suggesting that consuming a high-fiber diet can lower an individual’s risk for some cancers. Now, researchers are looking into whether a high-fiber diet can help patients with cancer fight a cancer diagnosis by boosting immunotherapy effectiveness. Previous research involving melanoma patients already determined that those with diets that were high in fiber responded better to immunotherapy. At the forefront of this latest research is assistant professor Brendan Guercio from the Wilmot Cancer Institute. Guercio has specialized in hematology/oncology and works as a medical oncologist who…

Continue Reading

MondayDec 18, 2023 10:30 am

How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

Clene, a late clinical-stage biopharmaceutical company, creates clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health The company’s lead investigational candidate, CNM-Au8(R), is currently in development as a disease-modifying treatment for people living with specific types of neurodegenerative disorders (“ND”), namely amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease, and multiple sclerosis (“MS”) Neurodegenerative disorders are characterized by neurodegeneration – the progressive loss of neuron structure, neuronal functions, and finally, the neurons themselves Nanotherapeutics are in development to stop or reverse neurodegeneration using novel approaches to address the mitochondrial deficits and bioenergetic crises…

Continue Reading

MondayDec 18, 2023 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline

The CDC estimates 1 out of 36 children in the United States have been diagnosed with Autism Spectrum Disorder – with a therapeutic market potential of $3.42 billion by 2030 PaxMedica’s mission is to help eliminate, reduce, or modulate the troublesome aspects of ASD, an unmet medical need in the industry CEO Howard Weisman shared important updates and achievements in the company’s pipeline, financial outlook, and future vision In a 2020 report released by the Centers for Disease Control and Prevention (“CDC”), it was estimated that 1 out of 36 children had been diagnosed with autism spectrum disorder (“ASD”) in…

Continue Reading

FridayDec 15, 2023 9:45 am

SOHM Inc. (SHMN) Releases New Product Line and Expands Manufacturing Operations in Carlsbad, California

SOHM is launching a line of 13 new chewables that offer a range of health benefits and expand the company's preventative care product portfolio The new line will be available online through Amazon.com and the company's direct-to-consumer website and will be showcased at industry conferences in 2024 SOHM is addressing its increased product demand by establishing a new CDMO GMP manufacturing facility in Carlsbad, California The new manufacturing facility is expected to be open by the end of 2023, and shareholders will be updated about its operations during its year-end 2023 report SOHM (OTC: SHMN), a pharmaceutical, nutraceutical, and cosmeceutical…

Continue Reading

WednesdayDec 13, 2023 9:00 am

SOHM Inc.’s (SHMN) New Gene-Editing Technology Holds Potential to Revolutionize the Field of Cardiology, With Superior Capabilities Over Other Gene-Editing Systems

SOHM recently acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired location of the target cell’s genome ABBIE is poised to facilitate drug development, with SOHM confident that its new gene-editing technology can revolutionize the field of cardiology by supporting new ways of discovering and developing drugs The ABBIE platform system is easy to operate and boasts high efficiency, low cost, and simple design ABBIE improves on some of the shortcomings of CRISPR-Cas9 as well as other gene-editing technologies, such as enabling researchers to edit genes of a large number of…

Continue Reading

TuesdayDec 12, 2023 9:00 am

Smart Trackers Could Detect Aging-Related Complications in Seniors

Wearable smart devices that track daily circadian rest-activity rhythms may allow for the detection of frailty-related health risks in seniors more than six years before the problems occur. A new study from Harvard-affiliated Brigham and Women’s Hospital has found that smart trackers could aid in the prediction of age-related health risks long before incidents happen. Older populations tend to face age-related declines in their psychological functions as they grow older, especially individuals who are genetically predisposed to develop certain age-related psychological conditions. In most cases, however, these conditions often become apparent once the illness has set in and symptoms have…

Continue Reading

MondayDec 11, 2023 11:15 am

SOHM Inc. (SHMN) Taps into UACI’s Robust Resources and Specialized Infrastructure for ABBIE Advancement

SOHM, a generic drug manufacturing and distributing innovator, announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its ABBIE platform In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure SOHM’s management is optimistic about the collaboration and is confident that this is but the first step toward deepening new lab operations It also marks a significant milestone, as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, just announced its development…

Continue Reading

MondayDec 11, 2023 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Is ‘One to Watch’

In November 2023, the company announced a purchase order from a Romanian company for seven TRACER 1000 ETDs to be deployed in a European airport Astrotech announced in June 2023 that its board unanimously rejected an unsolicited acquisition proposal from BML Investment Partners In May 2023, the company announced a purchase order from a Romanian company for 17 TRACER 1000 ETDs, to be delivered during calendar 2023 Astrotech confirmed test results from field trials of the AgLAB 1000-D2 mass spectrometer for hemp and cannabis producers, improving yields by an average of 24% In December 2022, the company effected a 1-for-30…

Continue Reading

FridayDec 08, 2023 9:00 am

The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles

The 2023 Nobel Prize in Chemistry, awarded to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, recognizes the power of nanotechnology Nanoscience is the study of structures and molecules whose sizes range between 1 and 100 nm, while nanotechnology is the technology that utilizes nanoscience in practical applications The applications of nanotechnology are wide-ranging, from industrial-scale catalysis and modern electronics to precision medicine and quantum technology Clene Inc., a late clinical-stage biopharmaceutical company, has applied nanotechnology alongside other science concepts in the development of catalytically active nanocrystals The catalytic activities…

Continue Reading

WednesdayDec 06, 2023 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study

During the live type-B meeting, PaxMedica discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One HAT, also called African Sleeping Sickness The FDA is allowing PaxMedica to use previous data from early tests of suramin to begin developing the drug for use in current cases of HAT PaxMedica received constructive feedback, which will aid in completing the remaining work necessary to file a New Drug Application (“NDA”), expected in the second half of 2024 The global ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000